SCI Pharmtech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for SCI Pharmtech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	48.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Mar 27

Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

Apr 07

There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

Mar 30

SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

Mar 08

SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Jan 25

Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Dec 30

Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Dec 29

Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

Dec 08

A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Nov 17

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SCI Pharmtech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:4119 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1,252	138	-791	106	N/A
3/31/2024	1,172	276	-384	480	N/A
12/31/2023	1,204	295	-814	216	N/A
9/30/2023	1,139	377	-805	245	N/A
6/30/2023	1,185	390	-726	307	N/A
3/31/2023	1,053	331	-988	395	N/A
12/31/2022	900	309	-871	297	N/A
9/30/2022	810	210	-874	262	N/A
6/30/2022	733	192	-690	341	N/A
3/31/2022	729	55	-1,011	-192	N/A
12/31/2021	864	56	-495	280	N/A
9/30/2021	1,227	-203	4	497	N/A
6/30/2021	1,677	-44	154	520	N/A
3/31/2021	2,229	193	720	940	N/A
12/31/2020	2,689	360	754	972	N/A
9/30/2020	2,711	728	797	979	N/A
6/30/2020	2,660	699	751	920	N/A
3/31/2020	2,536	615	586	753	N/A
12/31/2019	2,356	571	587	792	N/A
9/30/2019	2,300	592	433	673	N/A
6/30/2019	2,192	559	446	650	N/A
3/31/2019	2,118	550	506	696	N/A
12/31/2018	1,940	447	318	480	N/A
9/30/2018	1,809	396	394	526	N/A
6/30/2018	1,644	310	222	378	N/A
3/31/2018	1,398	201	N/A	263	N/A
12/31/2017	1,301	191	N/A	282	N/A
9/30/2017	1,226	166	N/A	269	N/A
6/30/2017	1,348	220	N/A	411	N/A
3/31/2017	1,586	311	N/A	562	N/A
12/31/2016	1,903	417	N/A	502	N/A
9/30/2016	1,994	444	N/A	606	N/A
6/30/2016	1,956	445	N/A	590	N/A
3/31/2016	2,013	438	N/A	544	N/A
12/31/2015	1,811	374	N/A	663	N/A
9/30/2015	1,795	360	N/A	509	N/A
6/30/2015	1,724	326	N/A	392	N/A
3/31/2015	1,560	294	N/A	381	N/A
12/31/2014	1,492	265	N/A	359	N/A
9/30/2014	1,460	254	N/A	303	N/A
6/30/2014	1,440	217	N/A	364	N/A
3/31/2014	1,330	170	N/A	540	N/A
12/31/2013	1,293	160	N/A	239	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4119's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 4119's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4119's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4119's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4119's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4119's Return on Equity is forecast to be high in 3 years time

SCI Pharmtech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 24% to NT$104

Consensus revenue estimates fall by 25%

Price target increased to NT$84.00

Consensus revenue estimates increase to NT$742.0m

Analysts update estimates

Price target lowered to NT$109

Recent updates

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: NT$0.52 (vs NT$1.86 in 2Q 2023)

SCI Pharmtech, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Upcoming dividend of NT$1.25 per share

First quarter 2024 earnings released: EPS: NT$0.37 (vs NT$0.59 in 1Q 2023)

SCI Pharmtech, Inc. Announces Board Changes

SCI Pharmtech, Inc. to Report Q1, 2024 Results on May 09, 2024

SCI Pharmtech, Inc. to Report Q1, 2024 Results on May 09, 2024

We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings

Full year 2023 earnings released: EPS: NT$2.70 (vs NT$2.88 in FY 2022)

SCI Pharmtech, Inc., Annual General Meeting, May 30, 2024

Third quarter 2023 earnings released: EPS: NT$0.33 (vs NT$0.45 in 3Q 2022)

New minor risk - Shareholder dilution

SCI Pharmtech, Inc. announced that it expects to receive TWD 120 million in funding

Second quarter 2023 earnings released: EPS: NT$1.86 (vs NT$1.31 in 2Q 2022)

Upcoming dividend of NT$0.25 per share at 0.2% yield

SCI Pharmtech, Inc. Announces Cash Dividend, Payable on September 1, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 24% to NT$104

Less than half of directors are independent

Now 21% undervalued

Consensus revenue estimates fall by 25%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SCI Pharmtech, Inc. Announces Appointment of General Manager of the Board of Directors

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to NT$84.00

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.31 (vs NT$1.98 in 3Q 2020)

Upcoming dividend of NT$0.50 per share

Second quarter 2021 earnings released: EPS NT$0.05 (vs NT$3.04 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.52 (vs NT$2.62 in 1Q 2020)

Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates

Consensus revenue estimates increase to NT$742.0m

There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings

Full year 2020 earnings released: EPS NT$4.53 (vs NT$7.19 in FY 2019)

SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?

SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years

Investor sentiment improved over the past week

Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates

Analysts update estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?

Price target lowered to NT$109

Investor sentiment deteriorated over the past week

New 90-day low: NT$112

Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?

A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)

Third quarter 2020 earnings released: EPS NT$2.38

Revenue beats expectations, earnings disappoint